(ACTU) Actuate Therapeutics - Ratings and Ratios
Elraglusib, Pancreatic, Cancer, Pediatric, Melanoma, Colorectal
ACTU EPS (Earnings per Share)
ACTU Revenue
Description: ACTU Actuate Therapeutics
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for various cancers, primarily in the United States. The companys lead product, elraglusib injection, is a glycogen synthase kinase-3 inhibitor currently undergoing Phase 2 trials for the treatment of metastatic pancreatic ductal adenocarcinoma, a highly aggressive and lethal form of cancer. Additionally, elraglusib is being tested in Phase 1/2 trials for refractory pediatric malignancies, including Ewing sarcoma, as well as metastatic melanoma and colorectal cancer, indicating a diverse pipeline with potential across multiple oncology indications.
The companys strategic focus on oncology aligns with a broader industry trend towards targeted therapies, where the emphasis is on developing treatments that address specific molecular mechanisms driving cancer progression. Given the high unmet medical need in the areas Actuate is targeting, successful development and commercialization of elraglusib could position the company favorably within the competitive biotechnology landscape.
Analyzing the provided
From a fundamental perspective, Actuate Therapeutics has a market capitalization of $205.67 million and a Return on Equity (RoE) of 50.40%, which is notably high. The absence of a Price-to-Earnings (P/E) ratio is expected for a company in the clinical-stage biopharmaceutical sector, as many such companies do not generate earnings due to their focus on research and development.
Forecasting the future performance of ACTU involves considering both the technical and fundamental aspects. Given the positive trend indicated by the SMA20 and SMA50, along with the companys promising pipeline, theres potential for growth. However, the biotech sector is known for its volatility, particularly around clinical trial results and regulatory decisions. If elraglusib demonstrates significant efficacy in its ongoing trials, this could be a substantial catalyst for the stock. Conversely, failure in these trials could lead to a decline. Based on the current trend and assuming positive trial outcomes, a potential target price could be near the 52-week high of $11.00, representing a 14% upside from the current price. Nonetheless, investors should be prepared for the inherent risks and volatility associated with clinical-stage biopharmaceutical companies.
Additional Sources for ACTU Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
ACTU Stock Overview
Market Cap in USD | 129m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2024-08-13 |
ACTU Stock Ratings
Growth Rating | -22.9 |
Fundamental | - |
Dividend Rating | 0.0 |
Rel. Strength | -17.1 |
Analysts | 4.67 of 5 |
Fair Price Momentum | 5.47 USD |
Fair Price DCF | - |
ACTU Dividends
Currently no dividends paidACTU Growth Ratios
Growth Correlation 3m | -27.7% |
Growth Correlation 12m | 6.9% |
Growth Correlation 5y | 6.9% |
CAGR 5y | -27.53% |
CAGR/Max DD 5y | -0.54 |
Sharpe Ratio 12m | -0.41 |
Alpha | -42.34 |
Beta | 1.191 |
Volatility | 97.78% |
Current Volume | 127.7k |
Average Volume 20d | 65.5k |
Stop Loss | 5.7 (-8.7%) |
As of July 09, 2025, the stock is trading at USD 6.24 with a total of 127,720 shares traded.
Over the past week, the price has changed by +1.79%, over one month by -28.36%, over three months by -10.47% and over the past year by -27.53%.
Neither. Based on ValueRay´s Analyses, Actuate Therapeutics is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of -22.91 and therefor a technical neutral rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ACTU is around 5.47 USD . This means that ACTU is currently overvalued and has a potential downside of -12.34%.
Actuate Therapeutics has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy ACTU.
- Strong Buy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to our own proprietary Forecast Model, ACTU Actuate Therapeutics will be worth about 6.5 in July 2026. The stock is currently trading at 6.24. This means that the stock has a potential upside of +4.81%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 29 | 364.7% |
Analysts Target Price | 29 | 364.7% |
ValueRay Target Price | 6.5 | 4.8% |